HK1062402A1 - Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops - Google Patents

Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops

Info

Publication number
HK1062402A1
HK1062402A1 HK04104813.3A HK04104813A HK1062402A1 HK 1062402 A1 HK1062402 A1 HK 1062402A1 HK 04104813 A HK04104813 A HK 04104813A HK 1062402 A1 HK1062402 A1 HK 1062402A1
Authority
HK
Hong Kong
Prior art keywords
psychotrops
desoxypeganine
intoxications
nervous system
central nervous
Prior art date
Application number
HK04104813.3A
Other languages
English (en)
Inventor
Klaus Opitz
Joachim Moormann
Thomas Hille
Frank Becher
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7682410&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1062402(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of HK1062402A1 publication Critical patent/HK1062402A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK04104813.3A 2001-04-24 2004-07-05 Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops HK1062402A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119863A DE10119863A1 (de) 2001-04-24 2001-04-24 Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen
PCT/EP2002/004278 WO2002087553A2 (de) 2001-04-24 2002-04-18 Verwendung von desoxypeganin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen

Publications (1)

Publication Number Publication Date
HK1062402A1 true HK1062402A1 (en) 2004-11-05

Family

ID=7682410

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04104813.3A HK1062402A1 (en) 2001-04-24 2004-07-05 Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops

Country Status (28)

Country Link
US (1) US20040132751A1 (hu)
EP (1) EP1383503B1 (hu)
JP (1) JP2004526791A (hu)
KR (1) KR20030094365A (hu)
CN (1) CN1638774A (hu)
AR (1) AR033469A1 (hu)
AT (1) ATE411024T1 (hu)
AU (1) AU2002325209B2 (hu)
BR (1) BR0209125A (hu)
CA (1) CA2445132C (hu)
CZ (1) CZ20032788A3 (hu)
DE (2) DE10119863A1 (hu)
DK (1) DK1383503T3 (hu)
EA (1) EA200301134A1 (hu)
ES (1) ES2316595T3 (hu)
HK (1) HK1062402A1 (hu)
HU (1) HUP0303921A3 (hu)
IL (1) IL158383A0 (hu)
MX (1) MXPA03009766A (hu)
MY (1) MY135676A (hu)
NO (1) NO20034741D0 (hu)
NZ (1) NZ529005A (hu)
PL (1) PL366845A1 (hu)
PT (1) PT1383503E (hu)
SI (1) SI1383503T1 (hu)
SK (1) SK287214B6 (hu)
WO (1) WO2002087553A2 (hu)
ZA (1) ZA200308042B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
ES2360547B1 (es) * 2009-11-02 2012-07-04 Consejo Superior De Investigaciones Científicas (Csic) Procedimiento de obtención de los alcaloides activos de la planta medicinal peganum harmala y su uso.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
DE3843239C1 (hu) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5602184A (en) * 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
DE19924951B4 (de) * 1999-05-31 2004-02-05 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
EP1231877A4 (en) * 1999-11-04 2009-03-18 Xel Herbaceuticals TRANSDERMALE ADMINISTRATION OF HUPERZIN

Also Published As

Publication number Publication date
DE50212901D1 (de) 2008-11-27
SI1383503T1 (sl) 2009-04-30
AU2002325209B2 (en) 2007-08-16
NZ529005A (en) 2007-11-30
WO2002087553A2 (de) 2002-11-07
MXPA03009766A (es) 2005-04-19
DE10119863A1 (de) 2002-11-07
ES2316595T3 (es) 2009-04-16
CN1638774A (zh) 2005-07-13
IL158383A0 (en) 2004-05-12
ATE411024T1 (de) 2008-10-15
BR0209125A (pt) 2004-07-27
EP1383503B1 (de) 2008-10-15
AR033469A1 (es) 2003-12-17
PL366845A1 (en) 2005-02-07
JP2004526791A (ja) 2004-09-02
EA200301134A1 (ru) 2004-04-29
CA2445132C (en) 2009-01-13
SK287214B6 (sk) 2010-03-08
HUP0303921A3 (en) 2011-03-28
DK1383503T3 (da) 2009-02-16
KR20030094365A (ko) 2003-12-11
NO20034741L (no) 2003-10-23
PT1383503E (pt) 2009-01-07
EP1383503A2 (de) 2004-01-28
HUP0303921A2 (hu) 2004-03-01
ZA200308042B (en) 2004-02-04
CA2445132A1 (en) 2002-11-07
SK13162003A3 (sk) 2004-02-03
CZ20032788A3 (en) 2004-05-12
NO20034741D0 (no) 2003-10-23
US20040132751A1 (en) 2004-07-08
MY135676A (en) 2008-06-30
WO2002087553A3 (de) 2003-02-27

Similar Documents

Publication Publication Date Title
EP1434801A4 (en) TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
IL176581A0 (en) Immunomodulatory compounds for the treatment of central nervous system disorders
ZA200608628B (en) Substituted morpholine compounds for the treatment of central nervous system disorders
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
EP1274444A4 (en) DRUGS FOR THE TREATMENT OF PSYCHIATRICAL OR ABUSUS-RELATED DISORDER
PL372425A1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
ZA200305691B (en) The use of substituted azetidione compounds for the treatment of sitosterolemia
ZA200702523B (en) Process for the purification of 1,4-butanediol
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
EP1654260A4 (en) 6-LOW HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EG23150A (en) Process for the purification of pharmacologically active proteins through cathionic enhance chromatography
EP1658072A4 (en) Compounds for the Treatment of Neurodegenerative Diseases
HUP0302530A3 (en) Process for the purification of 2-nitro-4-methylsulphonylbenzoic acid
EP1448193A4 (en) THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEAMIC CONDITIONS
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
HUP0500285A3 (en) Methods for the purification of levofloxacin
IL162455A0 (en) Compounds for the treatment of sexual dysfunction
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
EP1458694A4 (en) THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEAMIC CONDITIONS
HUP0303921A3 (en) Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops
AU2002325209A1 (en) Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops
GB0123145D0 (en) Apparatus for the purification of water
IL154378A0 (en) Compounds for the treatment of addictive disorders
SI1468686T1 (sl) S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj
EP1389129A4 (en) METHOD FOR TREATING RESPIRATORY DISEASES

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130418